Clinical therapy of Zisheng decoction recipe for chronic atrophic gastritis with intestinal metaplasia.
10.19540/j.cnki.cjcmm.20170919.004
- Author:
Xiu-Xia WU
1
;
Xian LI
1
;
Zhong-Qin DANG
1
;
Wen-Zhao LUO
1
;
Chang-Pu ZHAO
1
;
Kun YU
1
Author Information
1. Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou 450002, China.
- Publication Type:Journal Article
- Keywords:
Zisheng decoction recipe;
chronic atrophic gastritis;
clinical therapy;
famotidine;
intestinal metaplasia
- From:
China Journal of Chinese Materia Medica
2017;42(24):4882-4887
- CountryChina
- Language:Chinese
-
Abstract:
To explore the therapeutic effect and security of Zisheng decoction recipein treatment of the chronic atrophic gastritis (CAG) with intestinal metaplasia(IM). A total of 147 eligible cases were randomly divided into the traditional Chinese medicine group, Western medicine group and the combined group,47 cases in each group. Zisheng decoction recipe, famotidine, as well as Zisheng decoction recipe + famotidine were respectively given in the above three groups, with a treatment course of 30 d. The symptoms of traditional Chinese medicine, pathological score of gastric mucosa and the negative rate of Helicobacter pylori before and after treatment were observed in each group.The changes in pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (GAS-17) and endothelin-1 (ET-1)were also detected to compare the efficient and safety indexes in the three groups. The combined group was better than the traditional Chinese medicine groupand the Western medicine group in total effective rate (P<0.05), pathological score of gastric mucosa and the negative rate of Helicobacter pylori, and serum indexes improvement (P<0.05). The improvement in TCM symptom score was more obvious in traditional Chinese medicine group and combined group than the Western medicine group (P<0.05). In the comparison ofincidence of complications,heart, liver and renal dysfunction, the traditional Chinese medicine group (2 case,4.8%)< the combined group (7 case,15.2%)
